ClinicalTrials.gg
CompletedNCT00249873Updated Jun 15, 2015Results posted

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

A Phase 3 interventional study of clopidogrel (SR25990C) and placebo in Atrial Fibrillation and Vascular Risk, sponsored by Sanofi. Completed at 30 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-15.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7,554
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Atrial Fibrillation by Sanofi — none open to participants now, none under way, none of them phase 3. Atrial Fibrillation · Sanofi.

Enrollment
2nd of 20
7,554 · median 560
Started
2003
with 3 others
Phase 3
11 of 23
none open now
Registered
6th of 23
by date

Among the 23 studies in Atrial Fibrillation by Sanofi, this one is the 2nd largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2003, is one of 11 in phase 3, and was the 6th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

None of the 23 studies in Atrial Fibrillation by Sanofi is open now. The open studies under Atrial Fibrillation, anywhere →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Atrial Fibrillation by Sanofi as a file.
02

Study summary

The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular events such as stroke and heart attack during approximately three years of follow-up in patients with atrial fibrillation associated with at least one major risk factor of vascular event such as elderly, blood pressure increase, history of stroke or transient ischemic attack or left ventricular dysfunction etc. The study will also accept patients with atrial fibrillation and unwilling to take oral anticoagulant therapy.

03

Conditions studied

  • Atrial Fibrillation
  • Vascular Risk

Browse trials for

Keywords

  • Atrial fibrillation
  • Anticoagulant therapy
  • Thromboembolic prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for ACTIVE A patients must have in same time the three following conditions :

  • Evidence of atrial fibrillation either on one current (ECG) or two ECGs recorded at two weeks a part during 6 months prior to study enrollment.
  • Evidence of high risk of vascular events : at least one of the following risk criteria must be present :

    • are 75 years greater;
    • on treatment for systemic hypertension;
    • prior stroke, (TIA) or non-Central Nervous System (non-CNS) systemic embolus;
    • left ventricular dysfunction with (EF) estimated by echocardiogram or angiogram (radionuclide or contrast) to be \< 45%;
    • peripheral vascular disease (previous peripheral artery revascularization, limb and foot amputation, or the combination of current intermittent claudication and ankle arm systolic blood pressure ratio \< 0.9);
    • age 55 to 74 years and either; f1) diabetes mellitus requiring drug therapy, or f2) documented previous myocardial infarction or documented coronary artery disease.
  • To have either a to use an oral anticoagulant treatment or they are unwilling to take an oral anticoagulant treatment.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from ACTIVE if any of the following are present :

  • requirement for clopidogrel (such as recent coronary stent procedure)
  • requirement for oral anticoagulant (such as prosthetic mechanical heart valve);
  • prior intolerance to ASA or clopidogrel;
  • documented peptic ulcer disease within the previous 6 months;
  • prior intracerebral hemorrhage;
  • significant thrombocytopenia; ( count \< 50 x 10(9)/L)
  • psychosocial reason making study participation impractical;
  • geographic reason making study participation impractical;
  • ongoing alcohol abuse;
  • mitral stenosis,
  • pregnant or nursing woman or woman of child bearing potential and not on effective for at least one month prior to start of study or not willing to continue on birth control for duration of study; (severe comorbid condition such that the patient is not expected to survive 6 months;
  • patient currently receiving an pharmacologic agent;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
7,554 participants (actual)

Study arms

  • Experimental
    Clopidogrel + ASA

    Clopidogrel 75 mg once daily (od) plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)

    Drug: clopidogrel (SR25990C)

  • Placebo comparator
    Placebo + ASA

    Matching placebo of clopidogrel 75 mg od plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)

    Drug: placebo

Interventions

  • oral administration (tablets)

    Also known as: Plavix®

  • Drugplacebo

    oral administration (tablets)

06

What researchers measure

Primary outcomes

  1. First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication

    The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up : * stroke (nonfatal or fatal) * myocardial infarction (nonfatal or fatal) * non-CNS systemic embolism * vascular death The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group.

    Time frame: expected median follow-up of approximately 3 years

Secondary outcomes

  1. Occurrence of Stroke

    The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group.

    Time frame: expected median follow-up of approximately 3 years

  2. Death From Any Cause (Cardiovascular and Noncardiovascular)

    The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group.

    Time frame: expected median follow-up of approximately 3 years

  3. Adjudicated Major Bleedings

    The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug).

    Time frame: expected median follow-up of approximately 3 years

07

Results

Posted Mar 26, 2010

Participant flow

Patients were enrolled from June 2003 until May 2006. The study was conducted at 580 centers in 33 countries. The planned final follow-up visit date ensuring a median follow-up of three years was November 2008. The follow-up of the study was actually completed on March 2009 corresponding to an actual median follow-up of 3.5 years.

Participant flow — Overall Study
MilestoneClopidogrel + ASAPlacebo + ASA
Started37723782
Completed24422528
Not completed13301254
Withdrew: Not treated78
Withdrew: Significant thrombocytopenia98
Withdrew: Severe allergic reaction81
Withdrew: Serious haemorrhagic adverse event7430
Withdrew: Other serious adverse event8697
Withdrew: Qualifying condition not present2023
Withdrew: Contraindication to oral anticoagulant48
Withdrew: Withdrawal by subject504466
Withdrew: Lost to follow-up47
Withdrew: Minor bleeding9937
Withdrew: Non-compliance4146
Withdrew: Other non serious adverse event112108
Withdrew: Other contraindicated medication10
Withdrew: Patient not wish to continue after may0834
Withdrew: Physician withdrew consent5960
Withdrew: Open label clopidogrel required3142
Withdrew: Angiotensin ii receptor blocker required10
Withdrew: Oral anticoagulant required159157
Withdrew: Study drug intolerance50
Withdrew: Surgery/ procedure99
Withdrew: Event related to cardiac condition1221
Withdrew: Thromboembolic/outcome event82122

Outcome measures

PrimaryFirst Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication

The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up : * stroke (nonfatal or fatal) * myocardial infarction (nonfatal or fatal) * non-CNS systemic embolism * vascular death The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group.

Time frame:
expected median follow-up of approximately 3 years
Reported as:
Number · participants
First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication
participantsClopidogrel + ASAPlacebo + ASA
All components832924
- Myocardial Infarction (fatal or not)84105
- Stroke (fatal or not)285391
- Non-CNS systemic embolism5048
- Vascular death413380
Statistical analysis
  • Clopidogrel + ASA vs Placebo + ASA · Log Rank · p = 0.0133 (Cumulative incidence functions in each treatment group were calculated using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. The primary comparison was performed at the 5% level using a 2-sided Log rank test.) · Hazard ratio (hr): 0.89 · 95% CI 0.81 to 0.98The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of any component of the primary event for the clopidogrel group compared with the Placebo group.
SecondaryOccurrence of Stroke

The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group.

Time frame:
expected median follow-up of approximately 3 years
Reported as:
Number · participants
Occurrence of Stroke
participantsClopidogrel + ASAPlacebo + ASA
Occurrence of Stroke296408
Statistical analysis
  • Clopidogrel + ASA vs Placebo + ASA · Log Rank · p = <0.001 (Cumulative incidence functions in each treatment group were calculated using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. The primary comparison was performed at the 5% level using a 2-sided Log rank test.) · Hazard ratio (hr): 0.72 · 95% CI 0.62 to 0.83The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of stroke for the clopidogrel group compared with the Placebo group.
SecondaryDeath From Any Cause (Cardiovascular and Noncardiovascular)

The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group.

Time frame:
expected median follow-up of approximately 3 years
Reported as:
Number · participants
Death From Any Cause (Cardiovascular and Noncardiovascular)
participantsClopidogrel + ASAPlacebo + ASA
Death From Any Cause (Cardiovascular and Noncardiovascular)825841
Statistical analysis
  • Clopidogrel + ASA vs Placebo + ASA · Log Rank · p = 0.696 (Cumulative incidence functions in each treatment group were calculated using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. The primary comparison was performed at the 5% level using a 2-sided Log rank test.) · Hazard ratio (hr): 0.98 · 95% CI 0.89 to 1.08The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of death from any cause for the clopidogrel group compared with the Placebo group.
SecondaryAdjudicated Major Bleedings

The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug).

Time frame:
expected median follow-up of approximately 3 years
Reported as:
Number · participants
Adjudicated Major Bleedings
participantsClopidogrel + ASAPlacebo + ASA
Adjudicated Major Bleedings251162
Statistical analysis
  • Clopidogrel + ASA vs Placebo + ASA · Chi-squared · p = <0.001

Adverse events

Collected over From randomization through 28 days after the end of study drug treatment or the final follow-up visit. In both treatment groups, median duration of exposure was approximately 36 months, with a maximum of 62 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clopidogrel + ASA—1,154/3,772 (30.6%)2,542/3,772 (67.4%)
Placebo + ASA—1,069/3,782 (28.3%)2,502/3,782 (66.2%)
Most frequent serious events
Showing 10 of 872
Most frequent serious events
EventClopidogrel + ASAPlacebo + ASA
PneumoniaInfections and infestations139/3772128/3782
OsteoarthritisMusculoskeletal and connective tissue disorders28/377236/3782
Upper gastrointestinal haemorrhageGastrointestinal disorders28/37727/3782
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders28/377227/3782
Urinary tract infectionInfections and infestations23/377228/3782
SepsisInfections and infestations27/377219/3782
Gastrointestinal haemorrhageGastrointestinal disorders26/37729/3782
FallInjury, poisoning and procedural complications24/377219/3782
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)24/377216/3782
Renal failure acuteRenal and urinary disorders22/377223/3782
Most frequent other events
Showing 10 of 17
Most frequent other events
EventClopidogrel + ASAPlacebo + ASA
Any Infections and infestationsInfections and infestations994/3772961/3782
Any Gastrointestinal disordersGastrointestinal disorders806/3772763/3782
Any Nervous system disordersNervous system disorders661/3772682/3782
Any Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders532/3772623/3782
Any General disorders and administration site conditionsGeneral disorders582/3772541/3782
Any Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders538/3772510/3782
Any Vascular disordersVascular disorders440/3772414/3782
Any Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications433/3772353/3782
Any Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders337/3772289/3782
Any Cardiac disordersCardiac disorders301/3772314/3782

Baseline characteristics

Age, Customized
Age, Customized(participants)Clopidogrel + ASAPlacebo + ASATotal
18 to <65 years9319351866
65 to <75 years129112582549
>= 75 years155015893139
Age, Continuous
Age, Continuous(years)Clopidogrel + ASAPlacebo + ASATotal
Mean70.9 ± 10.271.1 ± 10.271.0 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Clopidogrel + ASAPlacebo + ASATotal
Female156015973157
Male221221854397
CHADS2 Score
CHADS2 Score(participants)Clopidogrel + ASAPlacebo + ASATotal
0105101206
1136013382698
2126313152578
>2104010282068
Missing404
Sitting Systolic Blood Pressure
Sitting Systolic Blood Pressure(participants)Clopidogrel + ASAPlacebo + ASATotal
<120 mmHg6036201223
>=120 mmHg316631596325
Missing336
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)Clopidogrel + ASAPlacebo + ASATotal
Mean28.370 ± 5.57528.459 ± 6.02228.415 ± 5.803
08

Study locations

30 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • Sanofi-Aventis Administrative Office
    Macquarie Park, Australia
  • Sanofi-Aventis
    Wien, Austria
  • Sanofi-aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Santiago, Chile
  • Sanofi-Aventis Administrative Office
    Praha, Czech Republic
  • Sanofi-Aventis Administrative Office
    Horsholm, Denmark
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Athens, Greece
  • Sanofi-Aventis Administrative Office
    Causeway Bay, Hong Kong
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Milano, Italy
  • Sanofi-Aventis Administrative Office
    Kuala Lumpur, Malaysia
  • Sanofi-Aventis Administrative Office
    Mexico, Mexico
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Lysaker, Norway
  • Sanofi-Aventis Administrative Office
    Warszawa, Poland
  • Sanofi-Aventis Administrative Office
    Porto Salvo, Portugal
  • Sanofi-Aventis Administrative Office
    Singapore, Singapore
  • Sanofi-Aventis Administrative Office
    Midrand, South Africa
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-Aventis Administrative Office
    Geneva, Switzerland
  • Sanofi-Aventis Administrative Office
    Taipei, Taiwan
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
09

References and documents

Publications

  • ACTIVE Investigators; Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009 May 14;360(20):2066-78. doi: 10.1056/NEJMoa0901301. Epub 2009 Mar 31. PubMed 19336502 ↗
  • Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010 Oct 28;363(18):1704-14. doi: 10.1056/NEJMoa1008410. Epub 2010 Aug 29. PubMed 20979470 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2005
First posted
Nov 7, 2005
Start
Jun 2003
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Mar 26, 2010
Last update
Jun 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00249873
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 7, 2005
Start date
Jun 2003
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Mar 26, 2010
Last update
Jun 15, 2015

Study contacts

Philippe YUSUF, Prof.
study chair · Hamilton Health Sciences Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion